Guggenheim Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $30

Benzinga Newsdesk www.benzinga.com Positive 50.4%

Neg 0% Neu 0% Pos 50.4%

Guggenheim analyst Seamus Fernandez initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Buy rating and announces Price Target of $30.